1
|
Wilkins RC, Beaton-Green LA. Development of high-throughput systems for biodosimetry. RADIATION PROTECTION DOSIMETRY 2023; 199:1477-1484. [PMID: 37721060 PMCID: PMC10720693 DOI: 10.1093/rpd/ncad060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 01/24/2023] [Accepted: 02/08/2023] [Indexed: 09/19/2023]
Abstract
Biomarkers for ionising radiation exposure have great utility in scenarios where there has been a potential exposure and physical dosimetry is missing or in dispute, such as for occupational and accidental exposures. Biomarkers that respond as a function of dose are particularly useful as biodosemeters to determine the dose of radiation to which an individual has been exposed. These dose measurements can also be used in medical scenarios to track doses from medical exposures and even have the potential to identify an individual's response to radiation exposure that could help tailor treatments. The measurement of biomarkers of exposure in medicine and for accidents, where a larger number of samples would be required, is limited by the throughput of analysis (i.e. the number of samples that could be processed and analysed), particularly for microscope-based methods, which tend to be labour-intensive. Rapid analysis in an emergency scenario, such as a large-scale accident, would provide dose estimates to medical practitioners, allowing timely administration of the appropriate medical countermeasures to help mitigate the effects of radiation exposure. In order to improve sample throughput for biomarker analysis, much effort has been devoted to automating the process from sample preparation through automated image analysis. This paper will focus mainly on biological endpoints traditionally analysed by microscopy, specifically dicentric chromosomes, micronuclei and gamma-H2AX. These endpoints provide examples where sample throughput has been improved through automated image acquisition, analysis of images acquired by microscopy, as well as methods that have been developed for analysis using imaging flow cytometry.
Collapse
Affiliation(s)
- Ruth C Wilkins
- Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa K1A 1C1, Canada
| | - Lindsay A Beaton-Green
- Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa K1A 1C1, Canada
| |
Collapse
|
2
|
Wilkins RC, Rodrigues M, Beaton-Green LA. The Imaging Flow Cytometry-Based Cytokinesis-Block MicroNucleus (CBMN) Assay. Methods Mol Biol 2023; 2635:103-122. [PMID: 37074659 DOI: 10.1007/978-1-0716-3020-4_6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2023]
Abstract
The dose of ionizing radiation received by an individual can be determined using biodosimetry methods which measure biomarkers of exposure in tissue samples from that individual. These markers can be expressed in many ways, including DNA damage and repair processes. Following a mass casualty event involving radiological or nuclear material, it is important to rapidly provide this information to medical responders to assist in the medical management of potentially exposed casualties. Traditional methods of biodosimetry rely on microscope analysis, making them time-consuming and labor-intensive. To increase sample throughput following a large-scale radiological mass casualty event, several biodosimetry assays have been adapted for analysis by imaging flow cytometry. This chapter briefly reviews these methods with a focus on the most current methodology to identify and quantify micronuclei in binucleated cells within the cytokinesis-block micronucleus assay using an imaging flow cytometer.
Collapse
Affiliation(s)
- Ruth C Wilkins
- Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, ON, Canada.
| | | | | |
Collapse
|
3
|
Li J, Shen Z, Chen W, Feng Z, Fang L, Zhao J, Liu C, Du J, Cheng Y. Screening of miRNAs in White Blood Cell as a Radiation Biomarkers for Rapid Assessment of Acute Radiation Injury. Dose Response 2022; 20:15593258221123679. [PMID: 36132708 PMCID: PMC9483971 DOI: 10.1177/15593258221123679] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Accepted: 08/12/2022] [Indexed: 11/21/2022] Open
Abstract
Accidental radiation exposure is a threat to human health that necessitates
effective clinical diagnosis. Suitable biomarkers are urgently needed for early
assessment of exposure dose. Existing technologies being used to assess the
extent of radiation have notable limitations. As a radiation biomarker, miRNA
has the advantages of simple detection and high throughput. In this study, we
screened for miRNAs with dose and time dependent responses in peripheral blood
leukocytes via miRNA sequencing in establishing the animal model of acute
radiation injury. Four radiation-sensitive and stably expressed miRNAs were
selected out in the 24 h group of leukocyte miRNAs: mmu-miR-130b-5p,
mmu-miR-148b-5p, mmu-miR-184-3p, mmu-miR-26a-2-3p, and five were screened in the
48 h group of leukocyte miRNAs: mmu-miR-130b-5p, mmu-miR-423-5p, mmu-miR-676-3p,
mmu-miR-150-5p, mmu-miR-342-3p.The correlation curves between their expression
and irradiation dose were plotted. Then, the results were validated by RT-qPCR
in mouse peripheral blood. As a result, mmu-miR-150-5p and mmu-miR-342-3p showed
the highest correlation at 48h after irradiation, and mmu-miR-130b-5p showed
good correlation at both 24 h and 48 h after irradiation. In a conclusion, the
miRNAs that are sensitive to ionizing radiation with dose dependent effects were
selected out, which have the potential of forming a rapid assessment scheme for
acute radiation injury.
Collapse
Affiliation(s)
- Jiaxun Li
- College of Basic Medicine, Naval Medical University, Shanghai, China
| | - Zhefan Shen
- College of Basic Medicine, Naval Medical University, Shanghai, China
| | - Wei Chen
- Naval Medical Center, Naval Medical University, Shanghai, China
| | | | - Lan Fang
- Naval Medical University, Shanghai, China
| | | | - Cong Liu
- Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, China
| | - Jicong Du
- Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, China
| | - Ying Cheng
- Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, China
| |
Collapse
|
4
|
Chauhan V, Leblanc J, Sadi B, Burtt J, Sauvé K, Lane R, Randhawa K, Wilkins R, Quayle D. COHERE - strengthening cooperation within the Canadian government on radiation research. Int J Radiat Biol 2021; 97:1153-1165. [PMID: 34133252 DOI: 10.1080/09553002.2021.1941379] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 05/16/2021] [Accepted: 06/03/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE Canadian Organization on Health Effects from Radiation Exposure (COHERE) is a government initiative to better understand biological and human health risks from ionizing radiation exposures relevant to occupational and environmental settings (<100 mGy, <6 mGy/h). It is currently a partnership between two federal agencies, Health Canada (HC) and the Canadian Nuclear Safety Commission (CNSC). COHERE's vision is to contribute knowledge to reduce scientific uncertainties from low dose and dose-rate exposures. COHERE will advance our understanding by bridging the knowledge gap between human health risks and linkages to molecular- and cellular-level responses to radiation. Research focuses on identifying sensitive, early, and key molecular events of relevance to risk assessment. CONCLUSIONS The initiative will address questions of relevance to better apprize Canadians, including radiation workers and members of the public and Indigenous peoples, on health risks from low dose radiation exposure and inform radiation protection frameworks at a national and international level. Furthermore, it will support global efforts to conduct collaborative undertakings and better coordinate research. Here, we describe a historical overview of the research conducted, the strategic research agenda that outlines the scientific framework, stakeholders, opportunities to harmonize internationally, and how research outcomes will better inform communication of risk to Canadians.
Collapse
Affiliation(s)
- Vinita Chauhan
- Radiation Protection Bureau, Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Canada
| | - Julie Leblanc
- Directorate of Environmental and Radiation Protection and Assessment, Canadian Nuclear Safety Commission, Ottawa, Canada
| | - Baki Sadi
- Radiation Protection Bureau, Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Canada
| | - Julie Burtt
- Directorate of Environmental and Radiation Protection and Assessment, Canadian Nuclear Safety Commission, Ottawa, Canada
| | - Kiza Sauvé
- Directorate of Environmental and Radiation Protection and Assessment, Canadian Nuclear Safety Commission, Ottawa, Canada
| | - Rachel Lane
- Directorate of Environmental and Radiation Protection and Assessment, Canadian Nuclear Safety Commission, Ottawa, Canada
| | - Kristi Randhawa
- Directorate of Environmental and Radiation Protection and Assessment, Canadian Nuclear Safety Commission, Ottawa, Canada
| | - Ruth Wilkins
- Radiation Protection Bureau, Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Canada
| | - Debora Quayle
- Radiation Protection Bureau, Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Canada
| |
Collapse
|
5
|
Rodrigues MA, Probst CE, Zayats A, Davidson B, Riedel M, Li Y, Venkatachalam V. The in vitro micronucleus assay using imaging flow cytometry and deep learning. NPJ Syst Biol Appl 2021; 7:20. [PMID: 34006858 PMCID: PMC8131758 DOI: 10.1038/s41540-021-00179-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 02/16/2021] [Indexed: 02/07/2023] Open
Abstract
The in vitro micronucleus (MN) assay is a well-established assay for quantification of DNA damage, and is required by regulatory bodies worldwide to screen chemicals for genetic toxicity. The MN assay is performed in two variations: scoring MN in cytokinesis-blocked binucleated cells or directly in unblocked mononucleated cells. Several methods have been developed to score the MN assay, including manual and automated microscopy, and conventional flow cytometry, each with advantages and limitations. Previously, we applied imaging flow cytometry (IFC) using the ImageStream® to develop a rapid and automated MN assay based on high throughput image capture and feature-based image analysis in the IDEAS® software. However, the analysis strategy required rigorous optimization across chemicals and cell lines. To overcome the complexity and rigidity of feature-based image analysis, in this study we used the Amnis® AI software to develop a deep-learning method based on convolutional neural networks to score IFC data in both the cytokinesis-blocked and unblocked versions of the MN assay. We show that the use of the Amnis AI software to score imagery acquired using the ImageStream® compares well to manual microscopy and outperforms IDEAS® feature-based analysis, facilitating full automation of the MN assay.
Collapse
Affiliation(s)
| | | | - Artiom Zayats
- Amnis Flow Cytometry, Luminex Corporation, Seattle, WA, USA
| | - Bryan Davidson
- Amnis Flow Cytometry, Luminex Corporation, Seattle, WA, USA
| | - Michael Riedel
- Amnis Flow Cytometry, Luminex Corporation, Seattle, WA, USA
| | - Yang Li
- Amnis Flow Cytometry, Luminex Corporation, Seattle, WA, USA
| | | |
Collapse
|
6
|
Rodrigues MA. Automation of the in vitro micronucleus assay using the Imagestream ® imaging flow cytometer. Cytometry A 2018; 93:706-726. [PMID: 30118149 PMCID: PMC6174940 DOI: 10.1002/cyto.a.23493] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 04/16/2018] [Accepted: 04/25/2018] [Indexed: 12/02/2022]
Abstract
The in vitro micronucleus (MN) assay is a well‐established test for evaluating genotoxicity and cytotoxicity. The use of manual microscopy to perform the assay can be laborious and often suffers from user subjectivity and interscorer variability. Automated methods including slide‐scanning microscopy and conventional flow cytometry have been developed to eliminate scorer bias and improve throughput. However, these methods possess several limitations such as lack of cytoplasmic visualization using slide‐scanning microscopy and the inability to visually confirm the legitimacy of MN or storage of image data for re‐evaluation using flow cytometry. The ImageStreamX® MK II (ISX) imaging flow cytometer has been demonstrated to overcome all of these limitations. The ISX combines the speed, statistical robustness, and rare event capture capability of conventional flow cytometry with high resolution fluorescent imagery of microscopy and possesses the ability to store all collected image data. This paper details the methodology developed to perform the in vitro MN assay in human lymphoblastoid TK6 cells on the ISX. High resolution images of micronucleated mono‐ and bi‐nucleated cells as well as polynucleated cells can be acquired at a high rate of capture. All images can then be automatically identified, categorized and enumerated in the data analysis software that accompanies the ImageStream, allowing for the scoring of both genotoxicity and cytotoxicity. The results demonstrate that statistically significant increases in MN frequency when compared with solvent controls can be detected at varying levels of cytotoxicity following exposure to well‐known aneugens and clastogens. This work demonstrates a fully automated method for performing the in vitro micronucleus assay on the ISX imaging flow cytometry platform. © 2018 The Author. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of ISAC.
Collapse
|
7
|
Rodrigues MA, Beaton-Green LA, Wilkins RC, Fenech MF. The potential for complete automated scoring of the cytokinesis block micronucleus cytome assay using imaging flow cytometry. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 2018; 836:53-64. [PMID: 30389163 DOI: 10.1016/j.mrgentox.2018.05.003] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Revised: 03/27/2018] [Accepted: 05/03/2018] [Indexed: 12/21/2022]
Abstract
The lymphocyte Cytokinesis-Block Micronucleus (CBMN) assay was originally developed for the measurement of micronuclei (MN) exclusively in binucleated (BN) cells, which represent the population of cells that can express MN because they completed nuclear division. Recently the assay has evolved into a comprehensive cytome method to include biomarkers that measure chromosomal instability and cytotoxicity by quantification of nuclear buds (NBUDs), nucleoplasmic bridges (NPBs) and apoptotic/necrotic cells. Furthermore, enumeration of mono- and polynucleated cells allows for computation of the nuclear division index (NDI) to assess mitotic activity. Typically performed by manual microscopy, the CBMN cytome assay is laborious and subject to scorer bias and fatigue, leading to inter- and intra-scorer variability. Automated microscopy and conventional flow cytometry methods have been developed to automate scoring of the traditional and cytome versions of the assay. However, these methods have several limitations including the requirement to create high-quality microscope slides, lack of staining consistency and sub-optimal nuclear/cytoplasmic visualization. In the case of flow cytometry, stripping of the cytoplasmic membrane makes it impossible to measure MN in BN cells, calculate the NDI or to quantify apoptotic or necrotic cells. Moreover, the absence of cellular visualization using conventional flow cytometry, makes it impossible to quantify NBUDs and NPBs. In this review, we propose that imaging flow cytometry (IFC), which combines high resolution microscopy with flow cytometry, may overcome these limitations. We demonstrate that by using IFC, images from cells in suspension can be captured, removing the need for microscope slides and allowing visualization of intact cytoplasmic membranes and DNA content. Thus, mono-, bi- and polynucleated cells with and without MN can be rapidly and automatically identified and quantified. Finally, we present high-resolution cell images containing NBUDs and NPBs, illustrating that IFC possesses the potential for completely automated scoring of all components of the CBMN cytome assay.
Collapse
Affiliation(s)
| | - Lindsay A Beaton-Green
- Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Ontario, K1A 1C1, Canada
| | - Ruth C Wilkins
- Consumer and Clinical Radiation Protection Bureau, Health Canada, Ottawa, Ontario, K1A 1C1, Canada
| | | |
Collapse
|